



## **Alexo Therapeutics to Present ALX148 Clinical Data at the 32<sup>nd</sup> Annual Meeting of the Society for Immunotherapy of Cancer (SITC)**

**DUBLIN, Ireland and SOUTH SAN FRANCISCO, Calif. – Oct. 05, 2017** – Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system, today announced that it will be presenting data from its ongoing ALX148 phase 1 clinical program at the SITC 32<sup>nd</sup> Annual Meeting, Nov. 8-12, 2017 in National Harbor, Maryland.

### **Poster Presentation Information**

**Title:** A First-in-Human Study of ALX148: CD47 Blockade to Enhance Innate and Adaptive Immunity for Advanced Solid Tumor Malignancy and Non Hodgkin Lymphoma

**Category:** Clinical Trials (In Progress)

**Date:** Friday, November 10, 2017

**Time:** 12:30 p.m. – 2 p.m. and 6:30 p.m. – 8 p.m.

**Abstract Number:** P241

### **About Alexo Therapeutics**

Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRP $\alpha$  linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types. [www.alexotherapeutics.com](http://www.alexotherapeutics.com)

### **Contacts:**

Karen Sharma or Shai Biran, Ph.D.  
MacDougall Biomedical Communications  
(781) 235-3060  
[alexo@macbiocom.com](mailto:alexo@macbiocom.com)